All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
EquityEquity IPOs

IPO raises £7.5m for novel cancer treatment

London Stock Exchange, Paternoster Square, London, England, UK

BiVictriX Therapeutics plc, an emerging biotechnology company that develops new cancer therapies, began trading on London's alternative investment market (Aim) on Wednesday following its IPO.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree